A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine?

Autor: Geraint T. Williams, Richard H. Wilson, Graham R. Taylor, Rachel Butler, David Fisher, Susan D. Richman, S Kenny, Dominic Furniss, Rajarshi Roy, Matthew T. Seymour, Angela M. Meade, Elizabeth Hodgkinson, Richard Kaplan, Catherine Sampson, Malcolm Pope, Richard Adams, J.K. Pope, Tim Maughan, M.K. Parmar, John Bridgewater, Bharat Jasani, Laura L Nichols, Julian R. Sampson, Philip Quirke, Annmarie Nelson

Publikováno v: British Journal of Cancer
Maughan, T S, Meade, A M, Adams, R A, Richman, S D, Butler, R, Fisher, D, Wilson, R H, Jasani, B, Taylor, G R, Williams, G T, Sampson, J R, Seymour, M T, Nichols, L L, Kenny, S L, Nelson, A, Sampson, C M, Hodgkinson, E, Bridgewater, J A, Furniss, D L, Roy, R, Pope, M J, Pope, J K, Parmar, M, Quirke, P & Kaplan, R 2014, ' A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine? ', British Journal of Cancer, vol. 110, no. 9, pp. 2178-2186 . https://doi.org/10.1038/bjc.2014.182

Background:\ud \ud Molecular characteristics of cancer vary between individuals. In future, most trials will require assessment of biomarkers to allocate patients into enriched populations in which targeted therapies are more likely to be effective.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cff73b2cbc37e2e73c551850137aa559
https://eprints.gla.ac.uk/195585/1/195585.pdf

Developing a biomarker-stratified trial design in advanced colorectal cancer: The MRC FOCUS 3 feasibility study

Autor: M K B Parmar, Tim Maughan, John Bridgewater, Rachel Butler, Geraint T. Williams, Richard H. Wilson, Susan D. Richman, David E. Fisher, Bharat Jasani, Malcolm Pope, Philip Quirke, Annmarie Nelson, A Meade, Richard Kaplan, Matthew T. Seymour, Elizabeth Hodgkinson, S Kenny, J.K. Pope, Richard Adams

Publikováno v: Journal of Clinical Oncology. 29:TPS165-TPS165

It is likely that future trials for many solid tumours will be stratified by predictive/prognostic biomarkers in order to a) derive more homogeneous patient cohorts; b) "personalize" treatment interventions in relation to tumour (or host) phenotype;

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::71a66621618079783de741370ffc6636
https://doi.org/10.1200/jco.2011.29.15_suppl.tps165

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

Autor: Richard A, Adams, Angela M, Meade, Matthew T, Seymour, Richard H, Wilson, Ayman, Madi, David, Fisher, Sarah L, Kenny, Edward, Kay, Elizabeth, Hodgkinson, Malcolm, Pope, Penny, Rogers, Harpreet, Wasan, Stephen, Falk, Simon, Gollins, Tamas, Hickish, Eric M, Bessell, David, Propper, M John, Kennedy, Richard, Kaplan, Timothy S, Maughan, D, Cunningham

Publikováno v: The Lancet Oncology

Background: When cure is impossible, cancer treatment should focus on both length and quality of life. Maximisation of time without toxic effects could be one effective strategy to achieve both of these goals. The COIN trial assessed preplanned treat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24957249888572d5cbdd4dca29f06345

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.